- Eloxx Pharmaceuticals Inc To Host Investor and Analyst Call on Alport Syndrome TranscriptJun 27, 2023
- Eloxx Pharmaceuticals Inc Annual Shareholders Meeting TranscriptJun 22, 2023
- Eloxx Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Eloxx Pharmaceuticals Inc Topline ELX-02 Phase 2 Combination Results Call TranscriptSep 14, 2022
- Eloxx Pharmaceuticals Inc Topline ELX-02 Phase 2 Results Call and Webcast TranscriptNov 17, 2021
- Eloxx Pharmaceuticals Inc Analyst Call on Cystic Fibrosis Programs TranscriptOct 12, 2021
- Eloxx Pharmaceuticals, Inc., Zikani Therapeutics, Inc. - M&A Call TranscriptApr 01, 2021
- Q4 2020 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMar 11, 2021$154.8 (+2.65%)Earnings
- Q3 2020 Eloxx Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2020$108.8 (+4.21%)Earnings
- Q2 2020 Eloxx Pharmaceuticals Inc Earnings Call TranscriptAug 06, 2020$123.6 (-6.93%)Earnings
- Eloxx Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 20, 2020
- Q1 2020 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2020$116.4 (+14.12%)Earnings
- Q4 2019 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMar 05, 2020$138 (-9.92%)Earnings
- Eloxx Pharmaceuticals, Inc. - Special Call TranscriptJan 14, 2020
- Q3 2019 Eloxx Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2019$262 (-6.89%)Earnings
- Q2 2019 Eloxx Pharmaceuticals Inc Earnings Call TranscriptAug 07, 2019$242.8 (-9.40%)Earnings
- Q1 2019 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMay 09, 2019$474 (+7.63%)Earnings
- Eloxx Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2019
- Q4 2018 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMar 08, 2019$470.4 (+1.55%)Earnings
Eloxx Pharmaceuticals Inc To Host Investor and Analyst Call on Alport Syndrome Transcript
Ladies and gentlemen, thank you for standing by. And welcome to the Eloxx Pharmaceuticals webcast to discuss the unmet need in Alport syndrome and additional clinical data results from the topline ELX-02 Phase 2 clinical trial.
(Operator Instructions) I would now like to turn the conference over to your first speaker today, Sumit Aggarwal, Eloxx's President and Chief Executive Officer. Sumit, you may begin.
Thank you. Welcome, everyone, listening to the call today. We're excited about sharing the Alport syndrome overview and our results in ELX-02. This is a very exciting time for Eloxx as we plan our pivotal study in Alport.
On the next slide, you see that we're going to be making some forward-looking statements. Please refer to our SEC documents for detailed risk factors.
Now, turning over to the agenda on the next slide, we're really excited to have Professors Rachel Lennon and Detlef BĂ
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investorsâ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)